What is GHK-Cu? The Copper Peptide Explained
A complete research guide to GHK-Cu — one of the most studied naturally occurring copper complexes in tissue research, wound tissue remodelling and anti-ageing research.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a naturally occurring copper complex that has accumulated one of the most extensive research profiles of any peptide in tissue research and regenerative biology. Originally isolated from human plasma in 1973, it has since been studied across wound tissue remodelling, collagen synthesis, angiogenesis, and anti-inflammatory research — making it a foundational compound in dermal research protocols.
What is GHK-Cu?
GHK-Cu is a tripeptide copper complex consisting of the amino acid sequence Glycine-Histidine-Lysine bound to a copper (II) ion. It occurs naturally in human plasma, saliva, and urine, with plasma concentrations that decline significantly with age — a pattern that has made it a subject of intense interest in longevity and anti-ageing research.
The copper component is not incidental — it is central to GHK-Cu’s biological activity. The peptide acts as a high-affinity copper carrier, and the Cu²⁺ ion is essential for many of the enzymatic processes that GHK-Cu is observed to influence in research models.
Mechanism of Action
GHK-Cu operates through several distinct but interconnected mechanisms that collectively make it a multi-vector research compound:
Collagen Synthesis
GHK-Cu is one of the most studied compounds in collagen synthesis research. It has been observed to stimulate the production of collagen types I and III, as well as elastin and proteoglycans in dermal fibroblast models. The copper component appears to activate copper-dependent lysyl oxidase — the enzyme responsible for cross-linking collagen and elastin fibres to form the extracellular matrix.
Angiogenesis
GHK-Cu has been studied for its role in stimulating angiogenesis — the formation of new blood vessels. Research has examined its upregulation of VEGF and FGF (fibroblast growth factor) in wound tissue remodelling models, where adequate vascular supply is a critical rate-limiting factor.
Anti-inflammatory Activity
Research has demonstrated GHK-Cu’s ability to modulate inflammatory cytokine activity, including downregulation of TNF-α and other pro-inflammatory mediators. This anti-inflammatory profile is relevant to both wound tissue remodelling research and broader tissue research models.
DNA Repair and Gene Expression
More recent research has explored GHK-Cu’s effects at the genomic level. Studies have identified GHK-Cu as a modulator of gene expression affecting hundreds of genes related to wound tissue remodelling, inflammation, and metabolic activity — suggesting it may act as a biological signal for tissue repair activation.
GHK-Cu Research Applications
- Dermal Collagen Research: Fibroblast activation and collagen/elastin synthesis studies in skin tissue models.
- Wound tissue remodelling Models: Angiogenic and ECM remodelling studies in wound closure research.
- Anti-ageing Research: GHK-Cu plasma levels decline with age — research explores the relationship between this decline and age-associated tissue degradation.
- Anti-inflammatory Studies: Cytokine modulation and inflammatory pathway research.
- Gene Expression Research: GHK-Cu’s broad effects on gene regulation make it relevant to systems biology and genomics research.
GHK-Cu in Composite Research Stacks
GHK-Cu features prominently as the anchor compound in several tissue and regenerative research stacks:
| Stack | Composition | Total Reagent |
|---|---|---|
| GHK-Cu Standalone | GHK-Cu 100mg | 100mg |
| GLOW 70 | GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg | 70mg |
| KLOW 80 | GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg | 80mg |
The GLOW 70 and KLOW 80 stacks pair GHK-Cu’s collagen synthesis and angiogenic properties with BPC-157’s VEGF pathway activation and TB-500’s systemic cellular migration effects — creating a comprehensive multi-vector tissue repair research model.
GHK-Cu Data Sheet
| Parameter | Value |
|---|---|
| Structure | Tripeptide copper complex (Cu²⁺) |
| Sequence | Glycine-Histidine-Lysine |
| Concentration | 100mg |
| Format | Lyophilized |
| Purity | 99%+ Analytical Grade |
| Key Pathways | Collagen synthesis, VEGF, TNF-α modulation |
| Storage (Dry) | Cool, dark, low humidity |
| Storage (Reconstituted) | 2°C – 8°C |
| Research Use | In-vitro only |
Compound Profile
| Property | Detail |
|---|---|
| Sequence | Glycyl-L-histidyl-L-lysine (Gly-His-Lys) bound to a copper(II) ion |
| Molecular formula (GHK) | C14H24N6O4 — 340.4 g/mol for the free peptide; the copper complex is about 401–403 g/mol depending on its ionised form |
| CAS numbers | 49557-75-7 (GHK); 89030-95-5 (GHK-Cu, prezatide copper) |
| Discovery | Isolated from human plasma by Loren Pickart in 1973 |
| Endogenous levels | Reported at about 200 ng/mL in plasma at age 20, falling to about 80 ng/mL by age 604 |
| Other names | Copper tripeptide-1 (cosmetic ingredient name); prezatide copper |
| Regulatory status | Widely used as a topical cosmetic ingredient; no approved injectable medicine |
Key Published Research
- Discovery (1973): Pickart and Thaler identified a tripeptide in human serum that prolonged the survival of normal liver cells and stimulated growth in hepatoma tissue — later characterised as GHK.1
- Collagen synthesis (1988): GHK-Cu stimulated collagen synthesis in cultured fibroblasts at nanomolar concentrations, establishing its reputation in dermal research.2
- Wound matrix (2000): In experimental rat wounds, GHK-Cu modulated the expression of glycosaminoglycans and small proteoglycans such as decorin, which organise new extracellular matrix.3
- Skin regeneration pathways (2015): A review mapped GHK’s reported effects on fibroblast activity, antioxidant defence, anti-inflammatory signalling and stem-cell markers in skin models.4
- Gene-expression data (2018): Analyses of Broad Institute Connectivity Map data suggest GHK shifts the expression of a large number of human genes, many linked to tissue repair and antioxidant pathways.5
Regulatory & Research Status (2026)
- US FDA: Injectable GHK-Cu was one of twelve peptides removed from the FDA’s Category 2 compounding list in April 2026. It was not among the peptides reviewed by the Pharmacy Compounding Advisory Committee in July 2026, so its compounding status is unresolved.
- Cosmetics: GHK-Cu remains a common topical ingredient (copper tripeptide-1) in skin-care products in the UK and EU.
Evidence Quality & Limitations
Much of the GHK literature comes from Pickart and collaborators, and most mechanistic findings are from cell culture and animal wound models. Human studies are mostly small topical cosmetic studies, and gene-expression findings come from computational analyses of cell-line data rather than tissue measurements. The age-related decline in plasma GHK is well reported, but it has not been shown to cause age-related tissue changes.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243:85–7. PubMed
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238:343–6. PubMed
- Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 2000;115:962–8. PubMed
- Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19. PubMed
